NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Silexion Therapeutics Corp (SLXN) Stock Analysis

Silexion Therapeutics Corp (SLXN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

SLXN

$0.17

+$0.01 (+7.28%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SLXN with… →

SLXN Key Statistics

As of Oct 21, 2026
Trading
Open
$0.17
Previous Close
$0.15
Day's Range
0.16–0.17
52-Week Range
0.14–35.60
Volume
286.82K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.30
Valuation
Market Cap
$2.39M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−28.90
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$11.91M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
14.47M
1-Year Return
−99.53%
Dividend and dates
Avg Volume
10.12M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, SLXN closed at $0.17, −99.53% over 1 year.

Silexion Therapeutics Corp (SLXN) has a market capitalization of $2.39M.

In fiscal 2025, SLXN reported revenue of $0.00.

SLXN Stock Return by Calendar Year

Silexion Therapeutics Corp (SLXN) return since Apr 2021: what $10,000 became

1 year
$10,000 $47
−99.53%
5 years
$10,000 $1
−99.99%
Since Apr 2021
$10,000 $1
−99.99%

If you had invested $10,000 in Silexion Therapeutics Corp (SLXN) at the close on April 7, 2021, the earliest close on record here, it would have been worth $1 at the close on October 21, 2026: −99.99% in total, −80.71% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−99.14%
2025−93.63%
2024−81.47%
2023+7.75%
2022+4.03%
2021 (partial year)−3.20%

As of October 21, 2026.

SLXN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$11.91M—
2024$0.00−$16.44M—
2023$0.00−$4.94M—
2022$0.00−$3.22M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$11.63M−$11.91M—
2024$0.00—−$12.57M−$16.44M—
2023$0.00—−$4.68M−$4.94M—
2022$0.00—−$3.86M−$3.22M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Silexion Therapeutics Corp (SLXN) is capitalised at $2.39M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 13 employees.

SLXN last closed at $0.17 on October 21, 2026. That is +$0.01 (+7.28%) against the previous close. Over the past 52 weeks the price has ranged from $0.14 to $35.60. The latest close sits 16.2% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $11.91M. Earnings per share on a trailing basis come to −28.9.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at −0.3. Daily returns over the trailing 5 years annualize to a volatility of 420.56%. The trailing one-year total return is −99.53%. Across 5 years the annualized return works out at −83.76%.

Growth & Income

No dividend is on file for SLXN.

2026 is still running; the total return is −99.14% year to date. Across the complete calendar years on file, 2023 returned +7.75% and 2025 returned −93.63%. Of the 4 complete calendar years on file, 2 finished higher.

Peer Comparison

Silexion Therapeutics Corp (SLXN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Silexion Therapeutics Corp SLXN $2.39M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Silexion Therapeutics Corp has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Silexion Therapeutics Corp

Silexion Therapeutics Corp, a clinical-stage biotechnology company, discovers and develops RNA interference (RNAi) therapies for KRAS-driven cancers. Its products comprise SIL204 second-generation small interfering RNA (siRNA) undergoing phase 2/3 clinical evaluation for pancreatic cancer and silence mutant KRAS oncogene expression. The company was founded in 2008 and is headquartered in Ramat Gan, Israel.

Visit website →